The World Boxing Council (WBC) probe on Russian heavyweight boxer Alexander Povetkin, whose Sample A and B tested positive for banned substance meldonium, may take up to two months, Andrei Ryabinsky, the head of the Boxing World promotion company said.
WBC Heavyweight Champion Deontay Wilder of the United States (W36-L0, 35 KOs) was scheduled to hold his mandatory title bout against Povetkin (30-1, 22 KOs) on May 21 in Moscow, However, Russian boxer's doping Sample A had tested positive for meldonium shortly before the fight and the bout was suspended indefinitely. His Sample B also tested positive for the same substance.
"I personally believe that it [the investigation] will take a couple of months," Ryabinsky said in an interview with TASS on Friday.
Sample A revealed that the body system of the 36-year-old Russian fighter contained a low concentration of 0.07 micrograms. US sports channel ESPN later reported that before the positive doping result, Povetkin passed doping tests three times, namely on April, 7,8 and 11, and all his samples tested negative.
However, his doping test as of April 27 gave a positive indication for meldonium presence in his blood.
Wilder's management announced earlier it intended to demand from the Russian side a financial compensation of $4.6 million in case the bout was eventually cancelled.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete's blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
However, on April 13, WADA announced that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.
Meldronate is a cardiovascular preparation freely available for purchase at pharmacies across Russia without doctor's prescription.
--IANS
pur/vm
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
